Latest stories on ASND
Ascendis Pharma announces new data from PaTH Forward, PaTHway trials
The Fly61 · neutralproduct/pr
Ascendis Pharma Initiated With A Hold At Canaccord
The Fly48 · neutralanalyst
Ascendis Pharma price target lowered to $330 from $360 at Citi
The Fly34 · bearishanalyst
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
Stocktwits News58 · neutralproduct/pr
Ascendis Pharma Wins EMA Panel Backing for TransCon CNP in Pediatric Achondroplasia
TipRanks74 · bullishproduct/pr
Ascendis gets CHMP opinion recommending marketing authorization for TransCon CNP
The Fly74 · bullishproduct/pr
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
Seeking Alpha64 · neutralproduct/pr
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
GlobeNewswire74 · bullishproduct/pr
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
Business Insider74 · bullishproduct/pr
Ascendis Gets EMA Recommendation for Approval for Achondroplasia Treatment in Children
MarketWatch74 · bullishproduct/pr
Ascendis Pharma assumed with a Buy at UBS
The Fly63 · neutralanalyst
Ascendis Pharma Grants New Employee Warrants and Updates Articles of Association
TipRanks50 · neutralgeneral
New Peptide ETF From REX Looks Beyond GLP-1 Drugs
ETF Trends58 · neutralproduct/pr
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Business Insider56 · neutralproduct/pr
Asana, Zscaler, Appian, Atlassian, and Shopify Stocks Trade Up, What You Need To Know
Barchart56 · neutralgeneral
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
TipRanks63 · neutralm&a
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
Yahoo Finance71 · bullishgeneral
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
Yahoo Finance63 · neutralm&a
Ascendis Pharma: Back To Full Independence
Seeking Alpha34 · bearishgeneral
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end
Investing.com Analyst Ratings56 · neutralanalyst
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Ascendis Pharma falls -12.8%
The Fly38 · neutralearnings
Ascendis Pharma falls -12.1%
The Fly38 · neutralearnings
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James
The Fly42 · neutralanalyst
Raymond James downgrades Ascendis Pharma stock rating on partnership shift
Investing.com Analyst Ratings38 · neutralanalyst